Abstract
The Omicron variant of the SARS-CoV-2 virus carries mutations, which enable it to evade immunity conferred by vaccines and previous infections. We used a Cox proportional hazards model and a logistic regression model on individual-level data on all laboratory-confirmed SARS-CoV-2 infections in the Czech Republic to estimate the relative risk of infection, hospitalization, including severe states, for Delta and Omicron variants, adjusting for sex, age, previous infection, vaccine type and vaccination status. A recent (<2 months) two-dose vaccination reached VE 43% (95% CI: 42-44) against infection by Omicron compared to 73% (95% CI: 72-74) against Delta. A recent booster increased VE to 56% (95% CI: 55-56) against Omicron infection compared to 90% (95% CI: 90-91) for Delta. The VE against Omicron hospitalization of a recent two-dose vaccination was 45% (95% CI: 29-57), with a recent booster 87% (95% CI: 84-88). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI: 32-72) for recent vaccination, 90% (95% CI: 87-92) for a recent booster. Post-infection protection against Omicron hospitalization declined from 68% (95% CI: 68-69) at <6 months to 13% (95% CI: 11-14) at >6 months after a previous infection. A recent combination of a previous infection and vaccination was more protective then either alone with a slight benefit from a vaccination preceding an infection. Once infected, the OR for Omicron relative to Delta was 0.36 (95% CI: 0.34-0.38) for hospitalization, 0.24 (95% CI: 0.22-0.26) for oxygen therapy, and 0.24 (95% CI: 0.21-0.28) for ICU admission.
Significance Statement A nation-wide study shows that the protection of a previous infection or vaccination is lower against Omicron compared to Delta variant of SARS-CoV-2 and further declines with time. A booster dose or a combination of post-infection immunity with a vaccine conferred significant benefit to individuals in the Omicron wave in the Czech Republic, which further strengthens the importance of vaccination as an effective public health measure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding took lpace.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Director of the Institute of Health Information and Statistics of the Czech Republic has granted an ethical approval of the retrospective analyses presented in this paper.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors declare no competing interests.
Data Availability
Data are not publicly available but may be (partially) obtained from Institute of Health Information and Statistics of the Czech Republic for research purposes.
